TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
Item 8.01 Other Events.
On March 28, 2017, Tonix Pharmaceuticals Holding Corp. (the
Company) issued a press release announcing that the Company has
enrolled its first patient in its Phase 3 HONOR study of TNX-102
SL 5.6 mg, for the treatment of military-related posttraumatic
stress disorder.
A copy of the press release that discusses this matter is filed
as Exhibit 99.01 to, and incorporated by reference in, this
report. The information in this Current Report is being furnished
and shall not be deemed filed for the purposes of Section 18 of
the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.01 |
Press release, dated March 28, 2017, issued by Tonix Pharmaceuticals Holding Corp.* |
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session up +0.09 at 4.08 with 154,639 shares trading hands.
